TEE
SRPT icon

Tibra Equities Europe’s Sarepta Therapeutics SRPT Stock Holding History

Tibra Equities Europe’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-70,280
Closed -$9.29M – 241
2018
Q2 		$9.29M Buy
+70,280
New +$6.63M 1.39% 17

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Tibra Equities Europe's SRPT Position: Q3 2018 in Review

Tibra Equities Europe sold out of Sarepta Therapeutics (SRPT) in Q3 2018, closing a stake of 70,280 shares — an estimated $9.29M sold.

Tibra Equities Europe first reported a position in SRPT in Q2 2018 and held it in 1 quarter. The position peaked at $9.29M in Q2 2018. 344 funds tracked by Wall St. Rank hold SRPT as of Q3 2018.

  • Tibra Equities Europe reported no remaining Sarepta Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Tibra Equities Europe sold 70,280 Sarepta Therapeutics shares in Q3 2018, an estimated $9.29M.
  • Tibra Equities Europe first reported a position in Sarepta Therapeutics in Q2 2018 and held it in 1 quarter.
  • Tibra Equities Europe's Sarepta Therapeutics position peaked at $9.29M in Q2 2018.
  • 344 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2018.

Based on Tibra Equities Europe's 13F filing for Q3 2018, filed 13 Nov 2018.